174 related articles for article (PubMed ID: 12126896)
1. Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine.
Harbour DA; Gunn-Moore DA; Gruffydd-Jones TJ; Caney SM; Bradshaw J; Jarrett O; Wiseman A
Vaccine; 2002 Jul; 20(23-24):2866-72. PubMed ID: 12126896
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.
Patel M; Carritt K; Lane J; Jayappa H; Stahl M; Bourgeois M
Clin Vaccine Immunol; 2015 Jul; 22(7):798-805. PubMed ID: 25972402
[TBL] [Abstract][Full Text] [Related]
3. No benefit of therapeutic vaccination in clinically healthy cats persistently infected with feline leukemia virus.
Helfer-Hungerbuehler AK; Spiri AM; Riond B; Grest P; Boretti FS; Hofmann-Lehmann R
Vaccine; 2015 Mar; 33(13):1578-85. PubMed ID: 25698488
[TBL] [Abstract][Full Text] [Related]
4. A vector expressing feline mature IL-18 fused to IL-1beta antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus.
O'Donovan LH; McMonagle EL; Taylor S; Bain D; Pacitti AM; Golder MC; McDonald M; Hanlon L; Onions DE; Argyle DJ; Jarrett O; Nicolson L
Vaccine; 2005 May; 23(29):3814-23. PubMed ID: 15893619
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge.
Stuke K; King V; Southwick K; Stoeva MI; Thomas A; Winkler MT
Vaccine; 2014 May; 32(22):2599-603. PubMed ID: 24662705
[TBL] [Abstract][Full Text] [Related]
6. Feline leukemia virus immunity induced by whole inactivated virus vaccination.
Torres AN; O'Halloran KP; Larson LJ; Schultz RD; Hoover EA
Vet Immunol Immunopathol; 2010 Mar; 134(1-2):122-31. PubMed ID: 20004483
[TBL] [Abstract][Full Text] [Related]
7. Feline leukaemia virus: a review of immunity and vaccination.
Sparkes AH
J Small Anim Pract; 1997 May; 38(5):187-94. PubMed ID: 9179815
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of immunosuppressive effect and efficacy of an improved-potency feline leukaemia vaccine.
Haffer KN; Koertje WD; Derr JT; Beckenhauer WH
Vaccine; 1990 Feb; 8(1):12-6. PubMed ID: 2156386
[TBL] [Abstract][Full Text] [Related]
9. Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge.
Langhammer S; Hübner J; Jarrett O; Kurth R; Denner J
Antiviral Res; 2011 Jan; 89(1):119-23. PubMed ID: 21108970
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a feline leukemia virus vaccine in a controlled natural transmission study.
Lafrado LJ
J Am Vet Med Assoc; 1994 Mar; 204(6):914-7. PubMed ID: 8188511
[TBL] [Abstract][Full Text] [Related]
11. Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes.
Flynn JN; Hanlon L; Jarrett O
Immunology; 2000 Sep; 101(1):120-5. PubMed ID: 11012762
[TBL] [Abstract][Full Text] [Related]
12. Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up.
Hofmann-Lehmann R; Cattori V; Tandon R; Boretti FS; Meli ML; Riond B; Pepin AC; Willi B; Ossent P; Lutz H
Vaccine; 2007 Jul; 25(30):5531-9. PubMed ID: 17240486
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of diethylcarbamazine and 3'-azido-3'-deoxythymidine on feline leukemia virus lymphoma formation.
Nelson P; Sellon R; Novotney C; Devera C; Davidian M; English R; Tompkins M; Tompkins W
Vet Immunol Immunopathol; 1995 May; 46(1-2):181-94. PubMed ID: 7618257
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of three commercial feline leukemia virus vaccines against methylprednisolone acetate-augmented oronasal challenge exposure with virulent virus.
Pedersen NC; Johnson L
J Am Vet Med Assoc; 1991 Nov; 199(10):1453-5. PubMed ID: 1666102
[TBL] [Abstract][Full Text] [Related]
15. Feline leukaemia vaccine protection against viral latency.
Haffer KN; Sharpee RL; Beckenhauer WH
Vaccine; 1987 Jun; 5(2):133-5. PubMed ID: 3037814
[TBL] [Abstract][Full Text] [Related]
16. Control of feline leukaemia virus.
Weijer K; Uytdehaag FG; Osterhaus AD
Vet Immunol Immunopathol; 1989 May; 21(1):69-83. PubMed ID: 2549695
[TBL] [Abstract][Full Text] [Related]
17. Feline leukaemia virus (FeLV) and feline immunodeficiency virus infections in cats in the Pisa district of Tuscany, and attempts to control FeLV infection in a colony of domestic cats by vaccination.
Bandecchi P; Dell'Omodarme M; Magi M; Palamidessi A; Prati MC
Vet Rec; 2006 Apr; 158(16):555-7. PubMed ID: 16632529
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of feline leukemia virus vaccines.
Legendre AM
J Am Vet Med Assoc; 1994 Jul; 205(1):28. PubMed ID: 7928542
[No Abstract] [Full Text] [Related]
19. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
Osterhaus A; Weijer K; Uytdehaag F; Jarrett O; Sundquist B; Morein B
J Immunol; 1985 Jul; 135(1):591-6. PubMed ID: 2987351
[TBL] [Abstract][Full Text] [Related]
20. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.
Grosenbaugh DA; Leard T; Pardo MC
J Am Vet Med Assoc; 2006 Mar; 228(5):726-7. PubMed ID: 16506935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
